Discover and read the best of Twitter Threads about #Vasculitis22
Most recents (24)
Parallel Session V: Outcomes
Cardiovascular Burden in Patients With ANCA-Associated and Non-ANCA Associated Vasculitis
Dr. Ana B Arevalo
@ANABELENAREVAL2
#Vasculitis22
Cardiovascular Burden in Patients With ANCA-Associated and Non-ANCA Associated Vasculitis
Dr. Ana B Arevalo
@ANABELENAREVAL2
#Vasculitis22
Retrospective cohort study
AAV and non ANCA associated vasculitis compared
CV outcomes of interest.
#Vasculitis22
AAV and non ANCA associated vasculitis compared
CV outcomes of interest.
#Vasculitis22
Parallel Session V: Outcomes
Outcomes in ANCA-Associated Vasculitis: Validating a Renal Risk Score and Examining the Impact of Deprivation
Dr. Dominic McGovern
@DomP_McGovern
#Vasculitis22
Outcomes in ANCA-Associated Vasculitis: Validating a Renal Risk Score and Examining the Impact of Deprivation
Dr. Dominic McGovern
@DomP_McGovern
#Vasculitis22
Large national cohort in Scotland
All renal biopsies in Scotland from 2014-2020 included.
EGPA and double positivity excluded.
#Vasculitis22
All renal biopsies in Scotland from 2014-2020 included.
EGPA and double positivity excluded.
#Vasculitis22
Parallel Session V: Outcomes
Malignancies in Patients with AAV Treated Within the EUVAS Trials
Dr. Beatriz Sánchez Álamo
#Vasculitis22
Malignancies in Patients with AAV Treated Within the EUVAS Trials
Dr. Beatriz Sánchez Álamo
#Vasculitis22
Future cancer risk is a concern with immunosuppression for AAV.
ncbi.nlm.nih.gov/pmc/articles/P…
#Vasculitis22
ncbi.nlm.nih.gov/pmc/articles/P…
#Vasculitis22
Aims of this were to analyse results from extended follow up of patients who participated in EUVAS prospective RCTs.
#Vasculitis22
#Vasculitis22
Parallel Session V: Outcomes
Neurologic Involvement in Anca-Associated Vasculitis: Data From Multicenter Longitudinal Observational Study
Prof. Rula Hajj-Ali
@RulaHajjAliMD
#Vasculitis22
Neurologic Involvement in Anca-Associated Vasculitis: Data From Multicenter Longitudinal Observational Study
Prof. Rula Hajj-Ali
@RulaHajjAliMD
#Vasculitis22
Neurological involvement is common in AAV but has a variable presentation and not well studied.
#Vasculitis22
#Vasculitis22
Parallel Session IV: Paediatric Vasculitis
Monogenic Mimics of Behçet’s Disease
Dr Alice Burleigh
@burleigh_alice
#Vasculitis22
Monogenic Mimics of Behçet’s Disease
Dr Alice Burleigh
@burleigh_alice
#Vasculitis22
More Monogenic Mimics of Behçet’s Disease have been reported recently but not thoroughly investigated
Aim and 1-slide method
#Vasculitis22
Aim and 1-slide method
#Vasculitis22
Parallel Session IV: Paediatric Vasculitis
Characteristics of Pediatric ANCA Associated Vasculitis Among Racial/Ethnic Minorities- single center experience from United States
Dr Deepika Singh
#Vasculitis22
Characteristics of Pediatric ANCA Associated Vasculitis Among Racial/Ethnic Minorities- single center experience from United States
Dr Deepika Singh
#Vasculitis22
The aim of this study was to study the characteristics of pediatric patients from racial/ethnic minorities with AAV
1-slide methods
#Vasculitis22
1-slide methods
#Vasculitis22
Parallel Session IV: Paediatric Vasculitis
Differentiating MIS-C from Kawasaki Disease, the second most common vasculitis of childhood
Prof. Seza Ozen
#Vasculitis22
Differentiating MIS-C from Kawasaki Disease, the second most common vasculitis of childhood
Prof. Seza Ozen
#Vasculitis22
Both have similar clinical manifestation and laboratory findings
This study aims to identify features to differentiate between the 2 diseases
Pictures of diagnostic criteria of both diseases
#Vasculitis22
This study aims to identify features to differentiate between the 2 diseases
Pictures of diagnostic criteria of both diseases
#Vasculitis22
Parallel Session IV: Paediatric Vasculitis
Outcomes of kidney transplantation in childhood-onset ANCA-associated vasculitis. A multicentre study
Dr Giorgio Trivioli
#Vasculitis22
1/6
Outcomes of kidney transplantation in childhood-onset ANCA-associated vasculitis. A multicentre study
Dr Giorgio Trivioli
#Vasculitis22
1/6
Aim:
describe kidney transplantation outcomes among childhood-onset AAV
Inclusion criteria:
Diagnosis <18 yrs
Kidney transplant with at least 6 mo. follow-up
Exclusion criteria:
Kidney failure not due to AAV
Multi-organ transplant
21 centers
55 patients
#Vasculitis22
describe kidney transplantation outcomes among childhood-onset AAV
Inclusion criteria:
Diagnosis <18 yrs
Kidney transplant with at least 6 mo. follow-up
Exclusion criteria:
Kidney failure not due to AAV
Multi-organ transplant
21 centers
55 patients
#Vasculitis22
Baseline features, n=55:
Female 42 (76%)
Median age of diagnosis: 12
Deceased donor recipient: 35 (64%)
ANCA positivity at transplant: 14 (26%)
#Vasculitis22
Female 42 (76%)
Median age of diagnosis: 12
Deceased donor recipient: 35 (64%)
ANCA positivity at transplant: 14 (26%)
#Vasculitis22
Parallel Session III: Proteomics and Metabolomics
Context and Future
Dr. Andreas Kronbichler
@AKronbichler
Context and Future
Dr. Andreas Kronbichler
@AKronbichler
Parallel Session III: Proteomics and Metabolomics
Deconvolution of Transcriptomic Data Reveals Immune Cell Landscape of Inflammatory Infiltrates in Giant Cell Arteritis
Mr. Michal Zulcinski
#Vasculitis22
Deconvolution of Transcriptomic Data Reveals Immune Cell Landscape of Inflammatory Infiltrates in Giant Cell Arteritis
Mr. Michal Zulcinski
#Vasculitis22
Aim to use transcriptomic data from GCA positive patients to elucidate GCA pathogenesis and identify new pathways for therapeutic targeting.
#Vasculitis22
#Vasculitis22
Parallel Session III: Proteomics and Metabolomics
RNA Sequencing of Leukocytes Reveals Unique Differences Among Groups of Adult Patients with IgA Vasculitis
Mr. Matija Bajzelj
#Vasculitis22
RNA Sequencing of Leukocytes Reveals Unique Differences Among Groups of Adult Patients with IgA Vasculitis
Mr. Matija Bajzelj
#Vasculitis22
Methods
Included treatment naive IgA vasculitis
Leukocytes: mRNA isolated
Sequenced on Illumina.
#Vasculitis22
Included treatment naive IgA vasculitis
Leukocytes: mRNA isolated
Sequenced on Illumina.
#Vasculitis22
Parallel Session III: Proteomics and Metabolomics
Biomarker and Clinical Data Linkage to Determine the Minimal mRNA Set for Vasculitis Diagnosis
Ms. Gisela Pattarone
#Vasculitis22
Biomarker and Clinical Data Linkage to Determine the Minimal mRNA Set for Vasculitis Diagnosis
Ms. Gisela Pattarone
#Vasculitis22
Aim was to discriminate healthy volunteers with active vasculitis, active versus remission and future flares using BIOPRED targeted mRNA.
#Vasculitis22
#Vasculitis22
Used next generation sequencing to check a circulating immune profile of the study participants.
#Vasculitis22
#Vasculitis22
What do we know about the geographical variation in AAV?
Great work done, more to do.
nature.com/articles/s4158…
#Vasculitis22
Great work done, more to do.
nature.com/articles/s4158…
#Vasculitis22
Parallel Session I: Epidemiology
Characterisation of Systemic Vasculitis Outcomes Across a Nation: Do Different Models of Care Matter?
Dr. Rosemary Hollick
@RJ_Hollick
#Vasculitis22
Characterisation of Systemic Vasculitis Outcomes Across a Nation: Do Different Models of Care Matter?
Dr. Rosemary Hollick
@RJ_Hollick
#Vasculitis22
How can we configure services to better serve patients with vasculitis?
This is the VOICES study.
abdn.ac.uk/iahs/research/…
#Vasculitis22
This is the VOICES study.
abdn.ac.uk/iahs/research/…
#Vasculitis22
Parallel Session I: Epidemiology
Post-Induction ANCA Titer Does Not Predict Relapse, Mortality, or Renal Outcomes: A Target Trial Emulation Study
Dr. Zachary Wallace
@zach_wallace_md
#Vasculitis22
Post-Induction ANCA Titer Does Not Predict Relapse, Mortality, or Renal Outcomes: A Target Trial Emulation Study
Dr. Zachary Wallace
@zach_wallace_md
#Vasculitis22
Retrospective cohort study
PR3 or MPO AAV
3 outcomes of interest - death, ESKD or relapse
#Vasculitis22
PR3 or MPO AAV
3 outcomes of interest - death, ESKD or relapse
#Vasculitis22
Parallel Session II: Translational Vasculitis
Clinical features and treatment of patients with severe skin changes in IgA vasculitis: multicenter study
Pediatric Rheumatology European Society: Vasculitis Working Group
Dr Marija Jelusic
#Vasculitis22
Clinical features and treatment of patients with severe skin changes in IgA vasculitis: multicenter study
Pediatric Rheumatology European Society: Vasculitis Working Group
Dr Marija Jelusic
#Vasculitis22
Aim:
- evaluate prevalence of severe skin manifestations
- propose treatment
- describe clinical course, laboratory findings, and outcome
#Vasculitis22
- evaluate prevalence of severe skin manifestations
- propose treatment
- describe clinical course, laboratory findings, and outcome
#Vasculitis22
Methods:
- Observational retrospective multicenter study
- Medical records were used
- Pediatric patients with severe IgA (bullae, ulceration, & necrotic lesion)
- Control group with IgA but no severe skin manifestation
#Vasculitis22
- Observational retrospective multicenter study
- Medical records were used
- Pediatric patients with severe IgA (bullae, ulceration, & necrotic lesion)
- Control group with IgA but no severe skin manifestation
#Vasculitis22
Parallel Session I: Epidemiology
Age and Time-Dependent Increase i Incident Anti-Glomerular Basement Membrane (Anti-GBM) Disease – A Nationwide Cohort Study
Dr. Karl Nelveg-Kristensen
#Vasculitis22
Age and Time-Dependent Increase i Incident Anti-Glomerular Basement Membrane (Anti-GBM) Disease – A Nationwide Cohort Study
Dr. Karl Nelveg-Kristensen
#Vasculitis22
Parallel Session II: Translational Vasculitis
Neutrophil mediated T-cell suppression in ANCA vasculitis and Covid-19
Dr Aisling Ui Mhaonaigh
#Vasculitis22
Neutrophil mediated T-cell suppression in ANCA vasculitis and Covid-19
Dr Aisling Ui Mhaonaigh
#Vasculitis22
Parallel Session I: Epidemiology
FAIRVASC: A Semantic Web Approach to Rare Disease Registry Integration
Dr. Kris Mcglinn
#Vasculitis22
FAIRVASC: A Semantic Web Approach to Rare Disease Registry Integration
Dr. Kris Mcglinn
#Vasculitis22
Parallel Session II: Translational Vasculitis
Pneumocystis jirovecii pneumonia (PJP) among incident cases of giant cell arteritis and polymyalgia rheumatica
Dr Michael Putman
#Vasculitis22
Pneumocystis jirovecii pneumonia (PJP) among incident cases of giant cell arteritis and polymyalgia rheumatica
Dr Michael Putman
#Vasculitis22
PJP is a common pathogen in immunocompromised patients but how does this affect patients with GCA or PMR who receive glucocorticoids?
1-slide methods
#Vasculitis22
1-slide methods
#Vasculitis22
Parallel Session I: Epidemiology
Negative Versus Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis: A Case-Control Study
Ms Marta Casal Moura
@martacasalmoura
#Vasculitis22
Negative Versus Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis: A Case-Control Study
Ms Marta Casal Moura
@martacasalmoura
#Vasculitis22
Parallel Session II: Translational Vasculitis
Anti-complement C5a receptor antibodies are decreased in ANCA-associated vasculitis and associated with relapse
Dr Sebastian Klapa
#Vasculitis22
Anti-complement C5a receptor antibodies are decreased in ANCA-associated vasculitis and associated with relapse
Dr Sebastian Klapa
#Vasculitis22
Parallel Session I: Epidemiology
Air Pollution Risk Factors For Disease Onset Appear Shared Across Systemic Vasculitis and Other Autoimmune Diseases
Mr. Enock Havyarimana
@EnockBugaye
#Vasculitis22
Air Pollution Risk Factors For Disease Onset Appear Shared Across Systemic Vasculitis and Other Autoimmune Diseases
Mr. Enock Havyarimana
@EnockBugaye
#Vasculitis22
Harnessing data from UK Biobank to understand relationship between systemic vasculitis and air pollution.
#Vasculitis22
#Vasculitis22
Parallel Session II: Translational Vasculitis
Baseline soluble immune checkpoints predict relapse risk in PR3-ANCA vasculitis following rituximab induction therapy
Dr Andreas Kronbichler
@AKronbichler
#Vasculitis22
Baseline soluble immune checkpoints predict relapse risk in PR3-ANCA vasculitis following rituximab induction therapy
Dr Andreas Kronbichler
@AKronbichler
#Vasculitis22
An important question for all patients with AAV is can we predict relapse?
As we don't have many available biomarkers to help with this
Thus, could checkpoints be used?
Knowing that they can cause vasculitis themselves.
#Vasculitis22
As we don't have many available biomarkers to help with this
Thus, could checkpoints be used?
Knowing that they can cause vasculitis themselves.
#Vasculitis22
